X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XNK01 (evencaleucel) is an autologous NK cell-based drug candidate. It is under phase 2 clinical development in combination with Sarclisa for the treatment of patients with Multiple Myeloma.
Lead Product(s): Evencaleucel,Isatuximab
Therapeutic Area: Oncology Product Name: CellProtect
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2024
Details:
Under the research agreement, company's autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer.
Lead Product(s): NK Cell-based Therapy,Antibody
Therapeutic Area: Oncology Product Name: XNK04
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2023
Details:
The autologous NK cell-based product XNK03 is being investigated for the treatment of urothelial cancer, the most common form of bladder cancer. According to the American Cancer Society more than 80,000 new cases of bladder cancer are expected in the US in 2022 alone.
Lead Product(s): XNK03
Therapeutic Area: Oncology Product Name: XNK03
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Evencaleucel (XNK01), autologous ex vivo expanded and activated NK cells with potent anti-cancer activity for the treatment of patients with Multiple myeloma.
Lead Product(s): Evencaleucel
Therapeutic Area: Oncology Product Name: XNK01
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Karolinska University Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
First-in-human Phase I/II clinical trial with CellProtect (ACP-001), in a setting of consolidation treatment following high dose autologous stem cell transplantation in patients newly diagnosed with Multiple myeloma.
Lead Product(s): ACP-001
Therapeutic Area: Oncology Product Name: CellProtect
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
